Eganelisib

Eganelisib (IPI549) is a potent and selective PI3Kγ inhibitor with an IC50 of 16 nM. Eganelisib shows >100-fold selectivity over other lipid and protein kinases[1].

Product Specifications

CAS Number

[1693758-51-8]

Product Name Alternative

IPI-549

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PI3K

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/IPI549.html

Concentration

10mM

Purity

99.68

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(C1=C2N=CC=CN2N=C1N)N[C@H](C3=CC4=C(C(N3C5=CC=CC=C5)=O)C(C#CC6=CN(C)N=C6)=CC=C4)C

Molecular Formula

C30H24N8O2

Molecular Weight

528.56

Precautions

H302, H315, H319, H335

References & Citations

[1]Evans CA, et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K) -γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. ACS Med Chem Lett. 2016 Jul 22;7 (9) :862-7.|[2]De Henau O, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016 Nov 17;539 (7629) :443-447.